Pneumonia. Pneumonia, unspecified organism
Conditions
Interventions
Intervention 1: Intervention group: Probiotic group
In addition to standard antibiotic treatment and supportive care, patients in this group will receive 5 oral drops of Prokid drops daily, manufactured by Pourateb Pouya Pharmaceutical Company, Iran. E
patients in this group will receive only antibiotic treatment appropriate for age and severity of disease and standard supportive care, and no probiotics will be given to them. Antibiotic treatment wi
Sponsors
Gonabad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Months to 12 Years
Inclusion criteria
Inclusion criteria: Children of both sexes, aged 1 month to 12 years, with a diagnosis of pneumonia, who were admitted to the pediatric department. Informed consent from legal guardian
Exclusion criteria
Exclusion criteria: Patients with chronic underlying respiratory problems (such as cystic fibrosis), immunodeficiency, history of rheumatic fever, malignancies, and people who have received probiotics for any other underlying disease (such as inflammatory bowel disease) Patients with a history of pneumonia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Length of hospitalization. Timepoint: Beginning and end of hospitalization. Method of measurement: The duration of hospitalization is recorded as one of the outcome variables by reviewing the patients' medical records and calculating the time interval between the date of admission and the date of discharge. The data will be entered by the researcher in the standard data registration form. | — |
Secondary
| Measure | Time frame |
|---|---|
| Tachypnea (rapid breathing). Timepoint: During hospitalization, every 6 hours daily until discharge. Method of measurement: The condition of tachypnea will be assessed clinically by counting the number of breaths per minute by the treatment team and will be entered into the data recording form.;Tachycardia. Timepoint: During hospitalization, every 6 hours daily until discharge. Method of measurement: The patients' heart rate is measured every 6 hours during the hospitalization period by the treatment team, doctor or nurse, using a stethoscope, or a hospital vital signs monitoring device, and entered into the study data recording form. Based on the clinical guidelines of pediatrics and the table of normal heart rate ranges for age, at each visit, it will be determined whether the patient has tachycardia, an increase in heart rate above normal for age. The presence or absence of tachycardia is recorded as a qualitative variable, yes/no, and is examined as one of the secondary outcomes.;Arterial blood oxygen saturation (Spo2). Timepoint: During hospitalization, every 6 hours daily until discharge. Method of measurement: Using a fingertip pulse oximeter.;Cough. Timepoint: Daily during hospitalization. Method of measurement: Patient report and observation by parents or nurse, recorded in checklist.;Diarrhea. Timepoint: Daily during hospitalization. Method of measurement: In this study, diarrhea is defined by the World Health Organization as 3 or more loose or watery stools in 24 hours. In the case of infants and young children, a significant change in the frequency or consistency of stools from the child's normal pattern will also be considered a diagnostic criterion. Data will be collected by the researcher through clinical records, parent reports, or medical record review and entered into the study data recording form.;Empyema. Timepoint: Upon admission, and if the patient experiences worsening respiratory status, persistent fever, or suspected pleural fluid accumulati | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactmohammad tourani
Gonabad University of Medical Sciences
Outcome results
None listed